LEIDEN, NETHERLANDS -- (MARKET WIRE) -- March 15, 2007 -- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) and Pfizer Animal Health today announced the signing of a research license agreement for PER.C6®. The license agreement allows Pfizer Animal Health to use Crucell’s industry-leading PER.C6® cell technology in the production of a non-disclosed veterinary vaccine. Pfizer Animal Health has an option to convert the research license into a commercial agreement. Financial details were not disclosed.
